{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:17:42Z","timestamp":1783675062960,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Without effective intervention, primary hyperoxaluria type 1 (PH1) causes oxalate-induced kidney damage, leading to end-stage kidney disease and serious complications throughout the body. Although PH1 carries a heavy burden that impacts quality of life, literature on the experiences of those living with PH1 and caring for patients with PH1 is limited. This study aimed to describe the diagnostic journey in PH1 and characterize patients\u2019 and caregivers\u2019 self-reported experiences throughout the disease course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an observational study involving in-depth, semi-structured telephone interviews. Dominant trends were assessed using constant comparative analysis to identify themes in interviewees\u2019 descriptions of their experiences. Individuals aged\u2009\u2265\u200912\u00a0years and caregivers of children aged 6\u201317\u00a0years with genetically confirmed PH1 were eligible. Informed consent\/assent and ability to read and speak English were required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Interviewees (16 patients, 12 caregivers) reported a prolonged diagnostic journey due to low disease awareness, among other factors. Upon diagnosis, PH1 was frequently symptomatic, typically involving kidney stone-related symptoms but also potentially symptoms arising beyond the kidneys. PH1 most commonly led to worry and social impairment in adolescents, impaired physical function in adults, and a range of impacts on caregivers. In late-stage disease, dialysis was the most burdensome aspect of living with PH1 (due to time requirements, limitations from living with a catheter, etc.), and this burden was exacerbated by the COVID-19 pandemic. Benefits desired from PH1 management included reductions in laboratory measures of oxalate burden, kidney stone and urination frequency, and oxalate-related skin ulcers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PH1 greatly impacts patients\u2019 and caregivers\u2019 lives, primarily due to burdensome disease manifestations and associated emotional, physical, and practical impacts, as well as disease management challenges \u2013 particularly those related to dialysis in late-stage disease.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-023-03365-1","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T14:02:29Z","timestamp":1698328949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study"],"prefix":"10.1186","volume":"24","author":[{"given":"David","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"7","key":"3365_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649\u201358.","journal-title":"N Engl J Med"},{"key":"3365_CR2","unstructured":"Primary hyperoxaluria Danbury, CT: National Organization for Rare Disorders; 2020. https:\/\/rarediseases.org\/rare-diseases\/primary-hyperoxaluria\/. Accessed 11 May 2021."},{"issue":"3","key":"3365_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-021-00543-4","volume":"19","author":"K Shee","year":"2022","unstructured":"Shee K, Stoller ML. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol. 2022;19(3):137\u201346.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3365_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2215\/CJN.13821119","volume":"15","author":"DS Milliner","year":"2020","unstructured":"Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. 2020;15(7):1056\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3365_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S0889-8529(02)00030-0","volume":"31","author":"JR Asplin","year":"2002","unstructured":"Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927\u201349.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"3365_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","volume":"27","author":"P Cochat","year":"2012","unstructured":"Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729\u201336.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3365_CR7","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","volume":"27","author":"SM van der Hoeven","year":"2012","unstructured":"van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3855\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"3365_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.703305","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, et al. Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study. Front Med (Lausanne). 2021;8: 703305.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"3365_CR9","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3365_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ki.2009.435","volume":"77","author":"J Harambat","year":"2010","unstructured":"Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77(5):443\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"3365_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nephro.2016.08.002","volume":"13","author":"NA Soliman","year":"2017","unstructured":"Soliman NA, Nabhan MM, Abdelrahman SM, Abdelaziz H, Helmy R, Ghanim K, et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol Ther. 2017;13(3):176\u201382.","journal-title":"Nephrol Ther"},{"issue":"12","key":"3365_CR12","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00467-013-2444-5","volume":"28","author":"P Cochat","year":"2013","unstructured":"Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol. 2013;28(12):2273\u201381.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"3365_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ki.2014.222","volume":"86","author":"G Mandrile","year":"2014","unstructured":"Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86(6):1197\u2013204.","journal-title":"Kidney Int"},{"key":"3365_CR14","first-page":"151","volume":"5","author":"L Braun","year":"2012","unstructured":"Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151\u201363.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"12","key":"3365_CR15","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","volume":"5","author":"A Devresse","year":"2020","unstructured":"Devresse A, Cochat P, Godefroid N, Kanaan N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep. 2020;5(12):2136\u201345.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3365_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2215\/CJN.00430109","volume":"4","author":"K Abdel-Kader","year":"2009","unstructured":"Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3365_CR17","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/TP.0000000000003597","volume":"105","author":"A Devresse","year":"2021","unstructured":"Devresse A, Godefroid N, Anthonissen B, Labriola L, de Magn\u00e9e C, Reding R, et al. Liver transplantation in primary hyperoxaluria type 1: we have to find an alternative! Transplantation. 2021;105(4):e46\u20137.","journal-title":"Transplantation"},{"key":"3365_CR18","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.urology.2021.03.014","volume":"156","author":"K Shee","year":"2021","unstructured":"Shee K, Ahn J, Hamouche F, Mena J, Chi T, Stoller ML. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology. 2021;156:e147\u20139.","journal-title":"Urology"},{"issue":"13","key":"3365_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O\u2019Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216\u201326.","journal-title":"N Engl J Med"},{"key":"3365_CR20","unstructured":"Desch\u00eanes G, Cochat P, Magen D, van't Hoff W, Michael M, Sas D, et al. ILLUMINATE-B, a phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1) [poster]. Annual Meeting of the American Society of Nephrology. 2020."},{"key":"3365_CR21","doi-asserted-by":"crossref","unstructured":"Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, et al. ILLUMINATE-C, a single-arm, phase 3 study of lumasiran in patients with primary hyperoxaluria type 1 and CKD3b-5, including those on hemodialysis [presentation]. Annual Meeting of the American Society of Nephrology; 2021.","DOI":"10.1681\/ASN.20213210S1B2a"},{"key":"3365_CR22","doi-asserted-by":"crossref","unstructured":"Baum M, Langman C, Cochat P, Lieske J, Moochhala S, Hamamoto S, et al. PHYOX2: nedosiran reduced urinary oxalate excretion in patients with primary hyperoxaluria [poster]. Annual Congress of the American Society of Nephrology; 2021.","DOI":"10.1681\/ASN.20213210S1B9b"},{"issue":"8","key":"3365_CR23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/ndt\/gfaa135","volume":"36","author":"B Hoppe","year":"2021","unstructured":"Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria type 1 and end-stage renal disease: a phase II study. Nephrol Dial Transplant. 2021;36(8):1464\u201373.","journal-title":"Nephrol Dial Transplant"},{"key":"3365_CR24","unstructured":"CDER patient-focused drug development: U.S. Food & Drug Administration; 2021 [27 July 2021]. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/cder-patient-focused-drug-development. Accessed 18 Jan 2022."},{"key":"3365_CR25","unstructured":"Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2019. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 9 Aug 2021."},{"issue":"7","key":"3365_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2215\/CJN.13831119","volume":"15","author":"JE Lawrence","year":"2020","unstructured":"Lawrence JE, Wattenberg DJ. Primary hyperoxaluria: the patient and caregiver perspective. Clin J Am Soc Nephrol. 2020;15(7):909\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3365_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1020909529486","volume":"36","author":"H Boeije","year":"2002","unstructured":"Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391\u2013409.","journal-title":"Qual Quant"},{"issue":"6","key":"3365_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/13645579.2015.1005453","volume":"18","author":"AJB Fugard","year":"2015","unstructured":"Fugard AJB, Potts HWW. Supporting thinking on sample sizes for thematic analyses: a quantitative tool. Int J Soc Res Methodol. 2015;18(6):669\u201384.","journal-title":"Int J Soc Res Methodol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03365-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T21:54:39Z","timestamp":1730411679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03365-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03365-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval: Not applicable; the institutional review board (Advarra; Columbia, Maryland, USA) determined this protocol was exempt from need for approval as this was an observational study involving blinded telephone interviews and all data collected were anonymous and deidentified. All methods were carried out in accordance with relevant guidelines and regulations. Consent to participate: Participants provided informed consent\/assent\/parental permission (as applicable) to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Verbal consent for publication of anonymized and deidentified data was included in the informed consent\/assent form noting \u201cIf the results of this study are presented at scientific meetings or published in scientific journals, no information will be included that could identify you\/your child or you\/your child\u2019s answers personally.\u201d Consent\/assent was documented (signed and dated) by the researcher conducting the consent\/assent discussion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DD: Employee of Alnylam Pharmaceuticals and holds shares in Alnylam Pharmaceuticals. DG: Full-time employee of RTI Health Solutions, which was retained by the sponsor to conduct the study which is the subject of this manuscript. CR: Full-time employee of RTI Health Solutions, which was retained by the sponsor to conduct the study which is the subject of this manuscript. CG: Full-time employee of RTI Health Solutions at the time of this study, which was retained by the sponsor to conduct the study which is the subject of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}